Spark therapeutics, inc. (ONCE)
Income statement / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue from Contract with Customer, Excluding Assessed Tax

69,878

58,138

69,820

64,725

51,568

40,861

27,742

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

20,959

20,362

20,168

-

21,077

21,077

21,077

22,063

5,479

4,177

2,888

633

0

0

0

Operating expenses:
Cost of goods sold

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

159,522

147,696

130,976

125,254

118,557

125,069

132,534

135,160

131,187

114,230

100,863

86,380

76,812

66,224

55,947

46,029

35,656

28,511

21,297

16,351

0

0

0

Acquired in-process research and development

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Impairment of acquired in-process research and development

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Selling, general and administrative

148,457

136,355

129,697

124,895

128,884

126,220

123,200

111,124

91,252

76,661

60,609

48,070

38,473

32,884

28,541

23,352

19,181

14,826

10,532

7,863

0

0

0

Total operating expenses

320,210

291,557

271,393

258,364

257,044

262,324

281,024

270,584

254,087

220,789

172,604

145,582

115,285

99,109

84,488

69,381

55,587

44,088

32,579

24,964

0

0

0

Loss from operations

-250,332

-233,419

-201,573

-193,639

-198,067

-212,154

-254,556

-258,518

-233,127

-200,427

-152,435

-125,399

-94,207

-78,031

-63,410

-47,317

-50,107

-39,910

-29,690

-24,330

0

0

0

Equity Securities, FV-NI, Unrealized Gain (Loss)

-10,015

-8,330

-5,653

-5,078

4,291

2,619

364

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

10,041

10,660

10,511

9,994

9,264

7,662

5,673

4,073

2,812

2,269

2,070

1,746

1,237

723

441

192

119

64

0

-

0

0

-

Other income

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-250,306

-231,089

-86,715

-78,723

-74,512

-91,873

-248,519

-254,445

-226,040

-189,996

0

-

0

0

-

-

-

-

-

-

-

-

-

Income tax benefit (expense)

141

113

92

99

874

1,168

-953

-963

-1,817

-2,109

0

-

0

0

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-250,447

-231,202

-86,807

-78,822

-75,386

-93,041

-247,566

-253,482

-228,498

-196,049

-150,365

-123,653

-92,970

-77,308

-62,968

-47,125

-49,986

-39,842

-29,674

-24,324

0

0

0

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

634

634

634

0

-

0

0

-

Basic and diluted net loss per common share (in dollars per share)

-1.72

-

-1.43

-

-1.26

-

-1.25

-

-1.90

-

-1.70

-1.23

-1.07

-1.04

-0.95

-0.22

-0.70

-0.60

-0.58

-1.77

-1.22

-0.79

-0.86

Weighted average basic and diluted common shares outstanding (in shares)

38,747

-

37,906

-

37,498

-

37,046

-

34,258

-

30,771

30,583

30,368

27,456

26,807

24,696

24,138

24,080

17,925

5,712

5,531

5,246

5,100

Basic net income (loss) per common share (in usd per share)

-

-1.66

-

-

-

2.15

-

-

-

-2.40

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per common share (in usd per share)

-

-1.66

-

-

-

2.07

-

-

-

-2.40

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Basic

-

38,686

-

-

-

37,254

-

-

-

30,968

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

38,686

-

-

-

38,702

-

-

-

30,968

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-250,447

-231,202

-86,807

-78,822

-78,577

-105,580

0

-

0

0

-

-

-

-

-

-47,760

-51,328

-41,185

-31,016

-25,032

0

0

0

Other comprehensive income (loss):
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

1,144

1,662

1,604

586

-5,533

-6,200

-5,026

-5,163

126

612

-1,102

-801

56

-70

0

-

0

0

-

-

-

-

-

Unrealized gain (loss) on interest rate swap

-2,032

-1,645

-1,014

-641

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange translation adjustment

-168

-65

-59

-83

1,226

1,298

659

43

-1,222

-1,281

-588

7

-2

-3

0

-

0

0

-

-

-

-

-

Total comprehensive loss

-251,503

-231,250

-86,276

-78,960

-80,845

-99,337

-251,933

-258,602

-228,212

-195,472

-152,055

-124,447

-103,769

-85,416

0

-

0

0

-

-

-

-

-

Product sales, net
Revenue from Contract with Customer, Excluding Assessed Tax

39,534

41,482

34,336

26,973

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

3,352

2,660

1,632

1,008

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue
Revenue from Contract with Customer, Excluding Assessed Tax

30,344

16,656

35,484

37,752

43,378

43,437

24,049

12,066

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

8,579

4,546

8,788

6,907

5,111

5,111

869

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-